Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
1.545
-0.045 (-2.83%)
Nov 21, 2024, 1:14 PM EST - Market open
Atai Life Sciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Atai Life Sciences stock have an average target of 9.00, with a low estimate of 6.00 and a high estimate of 11. The average target predicts an increase of 482.52% from the current stock price of 1.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ATAI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +547.25% | Nov 18, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +611.97% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +870.87% | Aug 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +870.87% | Jul 31, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 21, 2024 |
Financial Forecast
Revenue This Year
454.41K
from 314.00K
Increased by 44.72%
Revenue Next Year
306.00K
from 454.41K
Decreased by -32.66%
EPS This Year
-0.81
from -0.25
EPS Next Year
-0.69
from -0.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.9M | 1.6M | 193.0M | ||
| Avg | 454,410 | 306,000 | 37.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 501.9% | 246.6% | 62,968.6% | ||
| Avg | 44.7% | -32.7% | 12,253.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.70 | -0.43 | -0.41 | ||
| Avg | -0.81 | -0.69 | -0.71 | ||
| Low | -0.87 | -0.82 | -0.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.